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ABSTRACT
Aims: To estimate pooled all-cause and cause-specific mortality risk for people with regular or 
problematic cocaine use.
Methods: Systematic review and meta-analysis of prospective or retrospective cohort studies (n≥30) 
of people with regular or problematic cocaine use with data on all-cause or cause-specific mortality. 
Of 2808 papers, 28 were eligible and reported on 21 cohorts with a total 170,019 individuals. Cohorts 
identified based on acute care for drug poisoning or other severe health presentation were excluded. 
Title/abstract screening was conducted by one reviewer; a second reviewer independently checked 
10% of excluded studies. Two reviewers conducted full-text screening. Data were extracted by one 
reviewer and checked by a second. A customised review-specific study reporting quality/risk of bias 
tool was used. Data on crude mortality rates (CMR) and standardised mortality ratios were extracted 
for both all-cause and cause-specific mortality. Standardised mortality ratios were imputed where not 
provided by the author using extracted data and information from the Global Burden of Disease Study 
2017. Data were pooled using a random-effects model. 
Results: The pooled all-cause crude mortality rate was 1.24 per 100 person-years (95% CI: 0.86, 1.78; 
n=16 cohorts), but with considerable heterogeneity (I2=98.8%). The pooled all-cause standardised 
mortality ratio was 6.13 (95%CI: 4.15, 9.05; n=16 cohorts). Suicide (SMR 6.26, 95%CI 2.84, 9.68), 
accidental injury (SMR 6.36, 95%CI 4.18, 9.68), homicide (9.38, 95%CI 9.38, 3.45, 25.48), and AIDS-
related mortality (SMR 23.12, 95%CI 11.30, 47.31) were all elevated compared with age and sex peers 
in the general population. 
Conclusions: There are elevated rates of mortality among people with regular or problematic cocaine 
use for traumatic deaths and deaths attributable to infectious disease. 
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INTRODUCTION
Cocaine manufacture is estimated to be at the highest level recorded and trafficking routes continue 
to expand globally (1). Greater availability has been accompanied by increased use, with an estimated 
0.37% (CI 0.31-0.42) of adults aged 15-64 years reporting use globally in 2017, equivalent to 18.0 (CI 
15.5-21.0) million people (1). Confluence of increasing availability and demand, coupled with 
indicators of increasing purity in some regions (1, 2), creates a higher risk environment for increased 
problematic use and health harms. 
The most common forms of cocaine are hydrochloride salt (typically a fine white powder) and base 
(‘crack’ cocaine), the latter appearing crystal- or rock-like and typically being higher purity (3). Cocaine 
produces stimulant effects, increasing heart rate and blood pressure, enhancing alertness and 
producing feelings of euphoria, with a half-life of 30-60 minutes (4). Regular use of cocaine is 
associated with adverse health effects, predominantly cardiovascular (e.g., arrhythmia, myocardial 
infarction, stroke) and psychiatric (e.g., psychotic episodes, suicidal ideation) in nature (5, 6). There 
are additional and greater severity health risks depending on route of administration, including 
respiratory problems with smoking (6), nasal ulceration with snorting (7) and bloodborne virus 
transmission with injection, as well as via form used (e.g., higher risk of dependence with crack versus 
powder cocaine; 6).
A systematic review of studies published until 2008 suggested that people with regular cocaine use 
had a four to eight times higher mortality risk than their age and sex peers in the general population(8). 
Only seven cohorts were located, so a lack of data precluded quantifying risks of cause-specific 
mortality or examination of reasons for variation in mortality rates. In the intervening period, there 
has been significant research exploring specific harms associated with cocaine use from which cause-
specific mortality estimates could be computed. Increased cocaine supply and demand globally and 
increasing poisoning deaths in a number of countries (e.g., United States; 9), including the highest rate 
of deaths in England and Wales observed in 2017 (10), makes it imperative that the magnitude of 
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mortality risk by cause be quantified for this population. As such, the aims of this systematic review 
were to:
1. Update the previous systematic review and perform meta-analysis to calculate pooled 
estimates of all-cause crude mortality rates (CMRs) and standardised mortality ratios (SMRs) 
for people with regular or problematic cocaine use globally (regardless of treatment status); 
and
2. Compute pooled estimates of cause-specific CMRs and SMRs, with a focus on those causes of 
death that could be causally related to regular or problematic cocaine use.
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METHODS
We report the systematic review methodology in accordance with the PRISMA guidelines (11) 
(Appendix A). This review protocol was registered with PROSPERO (CRD42018094623; Appendix B).
Search strategy and study screening
Medline, Embase and PsycINFO peer-reviewed literature databases were searched using the OVID™ 
interface/platform for articles published between 2009 and 22 February 2018. Relevant articles 
published between 1980 and 2008 were identified through a previous review conducted by the 
research team (8). In line with the previous review, search strings incorporating keywords and Medical 
Subject Headings (MeSH terms) related to cocaine/crack cocaine and mortality epidemiology were 
used to identify relevant articles (see Appendix C and D). Searches were limited to human literature. 
There were no restrictions on publication type or language; papers published in languages other than 
English were read via Google Translate or by a team member fluent in the language. 
Citations were imported into an Endnote™ library where duplicate citations were removed, and 
imported into Covidence, a web-based screening tool (12). Titles and abstracts were reviewed by one 
team member (LTT or research assistants); 10% of excluded studies were checked by a second person 
(AP) to monitor accuracy. Full-text articles were reviewed by two reviewers (LTT and AP or LD); 
discrepancies were resolved by a third reviewer (AP or LD). Reference lists for relevant systematic 
reviews identified in the peer-review literature search were hand searched for additional papers not 
already identified. 
Study eligibility
Studies were included if they were cohort or case-control studies or clinical trials (n≥30 people) where: 
i) at least 90% of the sample reported regular or problematic use of cocaine and ii) data on all-cause 
or cause-specific CMRs or SMRs were available (see Appendix E for detailed inclusion and exclusion 
criteria). This could include cohorts that were identified based on criteria other than cocaine use but 
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reported mortality data for a sub-group of people reporting regular or problematic cocaine use. 
Cohorts were defined as comprising people with regular or problematic use if individuals reported 
cocaine as their primary drug used, cocaine injection, cocaine dependence, treatment for cocaine 
dependence or other healthcare presentation related to the effects of cocaine. Cohorts defined by 
any cocaine use (with no other indicators of cocaine-related problems) were excluded. Cohorts 
defined by cocaine overdose/poisoning or other serious adverse health presentations with high 
mortality risk were excluded. This included cohorts defined by cardiovascular presentations related to 
cocaine exposure or HIV positive status; estimates from these studies are available in Appendix F. 
Data extraction
The data extraction worksheet was developed in Microsoft Excel based on the previous review.  
extraction was standardised through the use of a manual detailing data entry rules (8). Data were 
independently extracted by one reviewer (LTT) and checked by a second reviewer (TS). 
Variables extracted included study information (e.g., country of sample, length of follow-up, 
recruitment setting) and sample information (e.g., age, sex, percentage of sample injecting, 
percentage engaged in treatment, form of cocaine used). With respect to the outcomes of interest 
(all-cause and cause-specific mortality), we extracted sample size, number of observed deaths (all-
cause and cause-specific), person-years of observation, CMRs and SMRs. Data were extracted for 
specific causes of death which might be causally related to regular or problematic cocaine use through 
direct acute or chronic effects of the drug, or indirectly via other risk pathways (e.g., use of non-sterile 
injection equipment, high risk sexual behaviours). These causes of death comprised: drug-related, 
accidental injury, suicide, homicide, cardiovascular disease, respiratory disease, cancer, AIDS-related 
and digestive disease (the latter including liver diseases)(6). We also extracted International 
Classification of Diseases (ICD) codes or other information used to define cause-specific mortality. 
Where data for a study were incomplete, other published papers using the same cohort were sourced 
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to locate missing data. If supplementary information could not be located or did not detail the data 
needed, authors were contacted by email for additional information. 
Quality of reporting and risk of bias
There are no standard tools available for assessing risk of bias in descriptive studies reporting 
estimates of CMRs or SMRs. However, risk of bias tools for observational studies assessing the effects 
of exposures are under development and some domains of these tools are clearly relevant (13). We 
assessed risk of bias for the two domains that we considered most relevant for this type of study 
design: sample representativeness (i.e., the number of site locations and sample types) and outcome 
measurement (i.e., ascertainment of death by death registry/certificate versus indirect sources). 
Studies were rated as being at higher or lower risk of bias on these domains. The tool also measured 
three components of study reporting quality, comprising cohort description (i.e., age and/or sex data 
for the cohort), data completeness (i.e., numerator and denominator for outcome variable) and 
definition of cause-specific deaths (i.e., ICD codes or other information to define cause of death). 
Studies were assessed as having higher or lower risk or bias or quality reporting on each of these 
domains (see Appendix G for full details of tool). 
Data analysis
Calculation of CMR, SMR, and relative risks
If not reported by study authors, CMRs were calculated as per 100 person-years (100PY). Where 
person-years were not reported nor made available by the authors, an imputed CMR follow up 
calculation was undertaken using other data reported by the authors. This calculation was based on 
the assumption that deaths occurred halfway through the follow-up period so that each person who 
died contributed half the person-year follow-up of survivors (see Appendix H for formula and example 
computation). 
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Standardised mortality ratios (SMRs) represent the CMR ratio between those exposed to the risk and 
the general population (including those exposed to the risk). If not reported by study authors, SMRs 
were calculated by dividing the sample CMR by the CMR for the for the respective age, sex, location, 
and years from the Global Burden of Disease (GBD) 2017 study (14).  The GBD 2017 study used vital 
registration, verbal autopsy, registry, survey, policy, and surveillance data to model mortality 
estimates for 282 causes of death in 195 countries and territories.  Due to the nature of GBD data 
classification, a match between the GBD database and study classification for respiratory and digestive 
disease mortality was unable to be obtained resulting in CMRs being unable to be converted into 
SMRs. Standard errors of log-transformed CMRs and SMRs were estimated using Rothman Greenland 
method (15).    
Relative risks (RRs) comprise the ratio of mortality risk between those exposed to the risk (i.e., regular 
or problematic cocaine use) and those not exposed to the risk. With a low prevalence exposure such 
as regular and/or problematic cocaine use, SMRs and RRs should be similar, but RRs provide an 
estimate that is useful for further estimation of burden of disease. RRs were estimated from SMRs 
using the method described by Jones and Swerdlow (16) by adjusting the SMR by the proportion of 
the general population that experiences cocaine dependence (see Appendix H for the formulae).  
Pooling all-cause and cause-specific mortality CMR and SMR
DerSimonian and Laird random-effects meta-analysis (17) was conducted in STATA version 14.2(18) 
to pool all-cause and cause-specific CMR and SMR estimates. This allows for heterogeneity between 
and within studies (noting that each study could only contribute one estimate to each meta-analysis). 
Heterogeneity was quantified using the I2 statistic and described as  low (≤30%), moderate (>30% and 
≤50%), substantial (>50% and ≤90%) or considerable (>75% and 100%)(19).
Understanding variation in CMR and SMR
Sources of heterogeneity in all-cause CMR and SMR were investigated through univariate meta-
regressions, including aspects of the study design (including the percentage of the cohort that was 
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female, type of cocaine used, and geographical region) and the characteristics of the sample (including 
year of final follow-up, and recruitment setting). Variables were only included in meta-regressions if 5 
or more data points were available per variable. 
Sensitivity analyses
We undertook several addition analyses to examine potential impacts of our imputed metrics (CMRs, 
person years, SMRs) for studies that did not report all of these metrics upon the estimates generated 
in our meta-analyses. First, we generated estimated person years and CMRs for studies using our 
methods described above for studies that had reported all of these and compared the resulting 
estimates with the author-reported estimates; we found reasonable consistency for four out of seven 
studies (Appendix H). Second, we compared pooled estimated CMRs that included studies with 
imputed CMRs with the pooled estimates that only included author-reported CMRs. Finally, we 
contrasted the pooled estimated SMRs including studies where we used derived SMRs with pooled 
estimates that only used author-reported SMRs.
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RESULTS
As evident in the PRISMA study flow diagram in Figure 1, the search identified 2,808 papers, of which 
209 were screened in full. Of these 28 papers were deemed eligible, including 21 cohorts reported in 
primary publications and 7 secondary publications providing additional data for those cohorts 
reported in the primary publication (see Appendix I for excluded studies and Table 1 for details of 
included studies). 
All cohorts (or subsample of cohorts) included here wholly comprised people who reported regular or 
problematic cocaine use (see Appendix J). Cohort size ranged from 63 to 83,808 individuals (total 
170,019 individuals) and follow up of the cohort ranged between 58 to 468560 PY (total 1,012,147 
PY). Cohorts were recruited from nine countries: eight of which were classified as high-income and 
one (Brazil) as middle-high income. Over two-fifths of the cohorts (43%, n=9) were recruited from the 
United States, three cohorts from Spain and two from Denmark. Relative to the previous review (9 
cohorts)(8), 13 new cohorts were identified and three cohorts had additional published follow-up 
data. One study(20) from the original review was excluded as, on review for the current study, the 
population was not identified as reporting regular or problematic cocaine use. 
[Figure 1 here]
[Table 1 here]
Risk of bias and study reporting quality
Two-fifths (42.9%) of the cohorts were at risk of bias from poor representativeness; that is, the sample 
were recruited from a single site location or from a single sample type (e.g., people who were in 
treatment; see Table 2). Only three cohorts (14.9%) did not use an official death registry to identify 
deaths within the cohort, suggesting low risk of bias in outcome ascertainment. 
Outcomes for quality of reporting were mixed. Both age and sex characteristics of the cohort were 
reported for all except three cohorts (14.9%). However, half (52.4%) of the cohorts had incomplete 
Page 12 of 95Addiction
For Review Only
Cocaine use and mortality
13
mortality data, where the numerator or denominator for the main analyses of mortality were not 
reported.  Of the 17 cohorts for whom cause-specific mortality was reported, 10 (58.8%) did not 
provide definition(s) of the cause of death (see Appendix J for ICD codes used). 
[Table 2 here]
It is important to note that quality of reporting outcomes was assessed for the total cohort. In many 
instances, people with regular or problematic cocaine use were a subsample of a larger cohort of 
people who use drugs. Age/sex characteristics and both numerator and denominator for mortality 
specifically for the sample who report regular or problematic cocaine use were thus only available for 
8 (38%) and 5 (24%) cohorts, respectively (Table 2). 
All-cause mortality
Data from 16 cohorts yielded an all-cause CMR of 1.24 per 100 PY (95% CI: 0.86, 1.78) with substantial 
heterogeneity (I2=98.8%) (Table 3; Figure 2). Meta-regression analyses to explore sample and study 
characteristics that could explain high heterogeneity showed that the percentage of the cohort 
reporting injecting drug use was positively associated with higher CMRs (Table 4; Appendix L). 
Similarly, recruitment of the cohort from a single city (versus subnational/national recruitment) was 
associated with higher CMRs. There was little or no statistical evidence of an association of CMR with 
other variables explored (Table 4).
[Figure 2 here]
Authors of studies for seven cohorts reported all-cause SMRs; we imputed all-cause SMRs for a further 
9 cohorts. The pooled all-cause SMR across the 16 cohorts was 6.13 (95%CI: 4.15, 9.05), with 
substantial heterogeneity (I2 = 99.0%) (Table 3, Figure 2). This estimate was similar to that observed 
from the seven cohorts where all-cause SMRs were reported by the authors (5.58, 95%CI: 3,90, 7.99; 
I2 = 96.6%) (Appendix L). Excess mortality was particularly elevated among cohorts reporting lifetime 
injecting (13.74, 95% CI: 12.67, 14.90; I2=91.2%; n=5 cohorts). 
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[Table 3 here]
The percentage of the cohort that was female was negatively associated with excess mortality (Table 
4; Appendix L). Study characteristics associated with excess mortality comprised recruitment setting 
(with higher SMRs for cohorts recruited from hospital versus treatment services and other settings) 




Eight cohorts reported data on drug-related deaths. The definition of drug-related deaths was not 
provided for six cohorts; for the remaining two cohorts, ‘drug-related deaths’ comprised  poisoning 
deaths, deaths attributed to mental and behavioural disorders due to psychoactive substance use, 
and deaths from other causes that were thought to be drug-related by the authors following 
consultation with forensic and toxicological services (e.g., ICD-10 code J81 ‘pulmonary oedema’)(21). 
The pooled drug-related CMR was 0.34 per 100PY (95%CI: 0.10, 1.15), again with considerable 
heterogeneity (I2 = 98.6%) (Table 3, Figure 3). SMRs were only reported for two cohorts, with a very 
high pooled estimate observed (44.37, 95% CI: 37.28, 52.81; I2=63.7%) (Appendix L). We have not 
reported the pooled estimate for all cohorts - including those for whom we imputed SMR as the 
estimate was deemed unstable. 
[Figure 3 here]
Traumatic deaths: suicide, accidental injury, and homicide 
The pooled suicide CMR was 0.07 per 100PY (95%CI: 0.04, 0.10; I2=72.6%; n=8 cohorts), with both 
pooled accidental injury (n=6 cohorts) and homicide (n=3 cohorts) CMR estimated at 0.09 per 100PY 
(95%CI: 0.04, 0.22; I2=95.4% and 95%CI: 0.01, 1.54; I2=98.4% respectively) (Table 3, Figure 3). The 
pooled SMR based on author-reported and imputed estimates was 6.26 (95% CI: 2.84, 13.80; I2=94.4%) 
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for suicide, 6.36 (95% CI: 4.18, 9.68; I2=71.9%) for accidental injury and 9.38 (95% CI: 3.45, 25.48; 
I2=90.1%) for homicide (Table 3, Figure 4). Pooled estimates of the subsample of author-reported 
SMRs were higher for suicide and lower for accidental injury and homicide (Appendix L) but fell within 
the confidence intervals of the former estimates. There was substantial heterogeneity in these pooled 
CMR and SMR estimates. 
AIDS-related deaths
The pooled CMR for AIDS-related deaths based on 6 cohorts was 0.28 per 100PY (0.12-0.63; I2 = 95.1%) 
(Table 3, Figure 3). Only one study reported a SMR for AIDS-related deaths, with an excess mortality 
rate five times that expected in the general population (4.98, 95% CI 0.70, 35.34; Appendix L). The 
pooled SMR based on author-reported and imputed estimates was higher (23.12, 95%CI 11.30-47.31; 
I2 = 90.1%; n=6 cohorts) (Table 3, Figure 4) but fell within the confidence interval for the former 
estimate.
Digestive disease deaths
The pooled CMR for digestive diseases based on three cohorts was 0.14 per 100PY (95%CI: 0.03, 0.73; 
I2 = 96.1%). The SMR was only reported by authors for one cohort (1.90, 95%CI 1.20, 2.89). Three 
different cohorts provided CMRs and SMRs for liver-specific deaths, with these deaths occurring more 
than three times the expected rate (pooled SMR: 3.36, 95%CI 0.51, 22.10; I2 = 92.5%; n=3 cohorts) 
(Table 3, Figure 4).
Other causes of death
Pooled CMRs were derived from four cohorts for cardiovascular disease (0.13 per 100PY; 95%CI: 0.07, 
0.24; I2 = 77.3%), five cohorts for cancer (0.11, 95% CI: 0.50-0.25; I2 = 87.1%), and five cohorts for 
respiratory diseases (0.09, 95%CI 0.04, 0.17; I2 = 63.2%) (Table 3; Figure 3). These deaths were 
elevated relative to the expected rate, particularly respiratory diseases (pooled SMR: 24.12, 95% CI 
6.03, 96.43) (Table 3, Figure 4), although this estimate should be treated with caution being based on 
one cohort.  
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[Figure 4]
Mortality relative risks 
Estimated study-level mortality RRs for all-cause and cause-specific mortality are presented in 
Appendix K and are similar to SMRs.
We conducted several additional analyses to examine our approach to imputation of data. First, we 
generated estimated CMRs and person years for studies that had already reported all these metrics 
and found reasonable consistency across these (Appendix H). Second, we compared pooled estimates 
that did not include imputed CMRs with those that did, and again found reasonable consistency 
(Appendix L).  Finally, as noted earlier, we also contrasted pooled SMRs that only included author-
reported SMRs with those that included our imputed SMRs  (Appendix L); in some cases there were 
very few  or only one cohort that had author-reported SMRs, so there are few data, but the all-cause 
estimates were remarkably similar. Finally, we examined the  potential impact of the two very large 
cohorts on pooled estimates by generating pooled estimates without those two cohorts (22, 23). 
Pooled all-cause CMR was 1.23 per 100PY (95%CI 0.75, 2.02; I2=98.7%; n=15 cohorts) compared to 
1.24 per 100PY (95% CI: 0.86, 1.78; I2=98.8%; n=16 cohorts) including those cohorts; pooled accidental 
injury CMR was 0.13 per 100PY (95%CI 0.06, 0.25; I2 =82.5%; n=5 cohorts) compared to 0.09 per 100PY 
(95%CI: 0.04, 0.22; I2=95.4%; n=6 cohorts) including those cohorts; and pooled suicide CMR was 0.08 
per 100PY (95%CI 0.04, 0.15; I2=73.0%’ n=7 cohorts) compared to 0.07 per 100PY (95%CI: 0.04, 0.10; 
I2=72.6%; n=8 cohorts) including those cohorts.
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DISCUSSION
This review suggests that people with regular or problematic cocaine use have, on average, an excess 
mortality risk six times (95%CI four to nine times) the expected rate for their age-matched 
counterparts in the general population. The most highly elevated causes of deaths were drug-related 
or arising from traumatic causes (suicide, accidental injury or homicide) – all of which are preventable. 
Mortality was also elevated for communicable diseases (e.g., AIDS-related mortality) and other natural 
causes of death, including cardiovascular disease. These findings are consistent with the known effects 
of cocaine (6) and other risk pathways associated with these health outcomes (6).  The potential for a 
growing population of people with regular or problematic cocaine use – coupled with the current 
findings of elevated mortality risk – reinforces the need for expansion of evidence-based prevention 
and intervention efforts to reduce health harms.  
It is important to note that it is not the case that elevations in mortality necessarily reflect direct causal 
effects of cocaine use. In some instances elevated mortality may reflect other lifestyle factors and 
exposure to risk environments. But there are some causes of death for which there is good evidence 
of a direct causal impact. Cocaine carries a clear risk for cardiovascular events (e.g., heart attack, 
arrhythmia or stroke) (24). Risk of mortality can only be mitigated through reduced use. Yet, a major 
hurdle in reducing mortality associated with cocaine use is the lack of treatment options for cocaine 
dependence. There is no strong clinical evidence to support pharmacotherapies for cocaine 
dependence despite trials of various medicines(25-30). Psychosocial treatment (primarily contingency 
management) may decrease frequency of use and increase length of abstinence; longer-term impacts 
post-treatment are less clear (31). However, accessibility and affordability of psychosocial treatment 
are major issues in many countries, particularly for consumers of crack cocaine who are typically more 
socially marginalised relative to consumers of powder cocaine (32).
There are a range of secondary interventions that can address mortality risk pathways. Prevalence of 
HIV, HCV and other infectious diseases is often higher among people who use cocaine (and crack 
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cocaine specifically) relative to the general population (33), driving AIDS-related mortality and likely 
contributing to excess mortality from liver disease. Regular HIV and HCV testing coupled with access 
to HIV antiretroviral therapies and HCV direct-acting antiviral agents could significantly reduce HIV 
and HCV related mortality. Access to these services is suboptimal in almost all countries (34). 
Strategies to prevent transmission include provision of sterile needles and smoking pipes, free 
condoms, and pre-exposure prophylaxis for HIV and sexually transmitted infections (25). Rigorous 
evaluation of some of these interventions is yet to be undertaken (particularly with respect to their 
impacts on mortality) however efforts to directly engage people who smoke crack cocaine in particular 
are laudable as existing services targeted at people who inject drugs may not meet the needs of this 
group.  
Whilst preventable, reducing excess mortality due to traumatic causes (e.g., suicide, homicide, and 
accidental injury) is challenging. People with regular or problematic cocaine use are often from socio-
economically disadvantaged areas and are more likely to be exposed to environmental risk factors 
(e.g., violence, crime) than people who use other drugs (35). There is also a significant gap in evidence 
regarding interventions to reduce agitation related to stimulant intoxication and to manage violence 
risk more broadly amongst this group (36). Treatment for cocaine dependence thus needs to 
considerate of possible means for reducing the risk of injury and violent behaviour against a backdrop 
of broader environmental risk factors. CBT can also reduce suicide risk in substance-using populations 
(37). 
Strengths and limitations
There has been a significant growth in the literature on mortality among people who report regular 
or problematic cocaine use, with 13 new cohorts identified since the previous review in 2008(8).  
Cohorts were recruited from regions with the highest levels of cocaine use (i.e., North America, 
Western Europe and Latin America; 1), with Australasia and Central Europe being notable exceptions. 
There are limited data on cocaine use in many of the remaining regions (e.g., Asian and African regions; 
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1), highlighting the challenge of capturing health harms associated with regular or problematic cocaine 
use in these regions. 
Limitations of existing studies included uncertain representativeness of samples and poor reporting 
of methodological detail. Many of the cohorts included here were derived from a single sample type: 
typically, those individuals engaged with health services. Linkage of administrative data from 
healthcare services could be used in future studies. Secondly, data were often missing on how causes 
of death were defined and, where available, varied between studies. Although there are likely many 
contributors to heterogeneity in cause-specific mortality estimates, use of standardised definitions of 
cause-specific mortality (38) would reduce this potential source of variability. Nonetheless, it is 
important to acknowledge that varying definitions of causes likely contributed to heterogeneity across 
studies. Ideally, an approach where people used standardised definitions of causes of mortality might 
occur in future studies (e.g., 38), permitting some examination of whether this explains some of the 
variation observed.
We were thorough in searching for relevant studies, however, we may have missed eligible cohorts or 
made errors. Where necessary, we sought additional data from authors and we generated estimates 
of CMRs, SMRs and RRs where possible. There are potential biases introduced by our computation of 
person years where this was not reported, including impaired capacity to account for censoring, 
however sensitivity analyses showed relative consistency between imputed and study-reported 
person-years when we tested our approach on those studies which did provide the latter information. 
Computing SMRs and RRs was achieved by using estimates from the GDB study, the most 
comprehensive effort globally to estimate prevalence of cocaine dependence and of population-level 
cause-specific mortality (14). Pooled SMRs including estimates imputed from GBD typically fell within 
the confidence interval of the pooled SMRs from author-reported estimates only. We acknowledge 
that the GBD data may have some limitations and there was minor variability between pooled 
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estimates of author-reported SMRs versus author-reported and imputed SMRs. Reporting of all-cause 
and cause-specific SMRs in future work would improve confidence in existing estimates. Further, RRs 
should be treated with caution, being based on prevalence of cocaine dependence extracted from the 
GDB study, and likely of lower prevalence than regular and/or problematic cocaine use. 
Finally, some variability in cohort definition and study design should also be noted. This was explored 
via meta-regression and stratified meta-analyses; although cohort definition (i.e. meeting criteria for 
dependence vs not) was not associated with heterogeneity in CMR/SMR, other aspects of study design 
(e.g., recruitment setting, sampling frame) were associated with heterogeneity in estimates. 
Conclusions
There has been increased study of cohorts of people reporting regular or problematic cocaine use. For 
this reason, we could quantify excess mortality by cause of death in the current review. Synthesis of 
this evidence suggests people with regular or problematic cocaine use have, on average, six times 
(95%CI four to nine times) higher mortality risk than their age and sex peers in the general population. 
Excess mortality risk is particularly evident for traumatic causes of deaths and causes likely 
attributable to infectious diseases. These deaths are mostly preventable. A lack of treatment options 
for cocaine dependence mean current efforts rely heavily on other prevention and intervention 
strategies to address risk pathways to mortality.  
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Table 1: Characteristics of included studies
Study Country Years conducteda Sample N people
N person 
yearsb
1. Accurso, 2015(39) United States 1990-2010
People “abusing” cocaine and presenting for detoxification at Chemical 
Dependence Unit at John Hopkins Bayview Medical Center in Baltimore 
between 1990-1991 
315 5780*
2. Arendt, 2011(40) Denmark 1996-2006
People receiving publicly funded treatment for illicit substance use disorder 
and primarily using cocaine across Denmark between 1996-2006, identified 
from the Danish Substance Abuse Treatment Register
838 2571*
3. Barrio, 2013(41) Spain 2004-2010
People who reported regular cocaine use (≥ 52 days/last year) recruited from 
drug scenes and non-treatment settings in Madrid, Barcelona, and Seville, 
Spain, between 2004-2006
714 3922
4. Bohnert, 2017(23) United States 2006-2011
People receiving Veteran Health Administration (VHA) care in the 2005 
financial year diagnosed with cocaine use disorder and still alive in 2006 as 
identified using VHA National Patient Care Database
83808 468560*
5. Callaghan, 2013(22)
(Callaghan, 2012(42)) United States 1990-2005
People hospitalised with a cocaine use disorder diagnosis in California 
between 1990-2005 from the Patient Discharge Database 48949 395738





Spain 1997-2008 People starting drug treatment for cocaine use disorder in a publicly owned or funded treatment centre in Barcelona and Madrid between 1997-2007 11905 65849*
7. Dias, 2011(46)c Brazil 1992-2006
People who were consecutively admitted patients to Taipas General 
Hospital’s inpatient treatment for crack/cocaine dependence between 1992-
1994 
131 1182*
8. Gossop, 2002(47)c United Kingdom 1995-1999
People who self-reported cocaine misuse recruited to treatment programs 




(Tyndall, 2001(49)) Canada 1996-2011
People who injected cocaine in the 6 months prior to enrolling in the open 
cohorts of Vancouver Injection Drug Users Study (VIDUS) and AIDS Care 
Cohort to Evaluate access to Survival Sciences (ACCESS) in Vancouver 
between 1996-2011 
1719 11749
10. Hser, 2012(50) United States 2002-2010
Mothers enrolled in a drug treatment program with cocaine as the primary 
drug of concern between 2000-2002 across California as identified through 
California Treatment Outcome Project (CalTOP)
511 5471*
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11. Lopez, 2004 
(OFDT)(51)c France 1992-2001
People arrested in 1992, 1993, 1996 and 1997 for cocaine/crack use/dealing 
as identified through database of police questioning files for use of narcotics 2212 11496
12. Markota, 2016(52) United States 1999-2011
People aged 13-18 years old attending drug and alcohol treatment and with a 
positive cocaine urinary toxicology screen administered at clinical sites within 
Mayo Health Care System between 1999-2011
63 308*
13. Martell, 2009^(53) United States 2003-2005 People with cocaine and opioid dependence enrolled in a randomised clinical trial for cocaine vaccine from greater New Haven between 2003-2005 114 58*
14. Nielsen, 2011(54) Denmark 1999-2009
People diagnosed with cocaine abuse and at least one contact with a 
homeless shelter in Denmark between 1999-2009 as identified by the Danish 
Homeless Register
525 5362*




Italy 1989-2013 Individuals admitted to a public drug treatment for problems caused by primary use of cocaine in Bologna (North Italy) between 1989-2013 678 4753*
17. Ryb, 2009(59) United States 1983-1997 People discharged from R Adams Cowley Shock Trauma Center with a positive cocaine urinary toxicology screen at admission between 1983-1995 2451 15932*
18. Sanvisens, 2014(60) Spain 1985-2008
Patients admitted to hospital detoxification for primary cocaine abuse at one 
of three tertiary care facilities in Barcelona and the surrounding metropolitan 
area between 1985-2006
945 7155
19. van Haastrecht, 
1996(61)c Netherlands 1985-1993
People who are HIV+ and HIV- who self-reported injecting cocaine and were 
recruited in Amsterdam between 1985-1992 through “low-threshold” 
methadone programs and clinic workers for people who use drugs and 
engage in sex work.
632d 194
20. Vlahov, 2008(62) United States 1997-2002
People who inject drugs with self-reported injecting of cocaine everyday 
recruited from five U.S. cities between 1997-1999 through community-based 
outreach methods and enrolled in the second Collaborative Injection Drug 
Users Study (CIDUS-II) 
102 486
21. Wang, 2005(63)c United States 1988-2005
People who inject drugs who self-reported cocaine use in the previous 6 
months, recruited through community in Baltimore between 1988-1989 and 
1994-1998 and enrolled in AIDS Linked to Intravenous Experience study 
(ALIVE)
518# 3727
Note. Italics denotes associated secondary paper for the cohort; *Person years were not reported by study but calculated using formula within Appendix H; ^ Denotes that the study was a 
randomised controlled trial (RCT); # Denotes that the information was provided by the authors on request; a Period covers the start of recruitment until the end of follow-up; b Person-years 
were rounded to nearest whole number, though exact person-years reported were used for analysis; c Study was included in the previous review and information differs due to additional 
information being provided; d Study does not specify proportion of cohort that uses cocaine, but provides number of deaths within those who use cocaine. 
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Table 2: Summary of risk of bias and quality of study reporting
Study risk of bias Study reporting quality













Completeness of data 
(numerator/denominator)
Accurso, 2015(39)     NA  
Arendt, 2011(40)     NA  
Barrio, 2013(41)       
Bohnert, 2017(23)       
Callaghan, 2013(22)       
    Callaghan, 2012(42)     NA  
de la Fuente, 2016(43)     NA  
    Brugal, 2016(44)        
    Colell, 2018(45)     NA   
    Molist, 2018(21)        
Dias, 2011(46)       
Gossop, 2002(47)       
Hayashi, 2016(48)       
    Tyndall, 2001(49)       
Hser, 2012(50)       
Lopez, 2004 (OFDT)(51)       
Markota, 2016(52)       
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Martell, 2009^(53)     NA  
Nielsen, 2011(54)       
O’Driscoll, 2001(55)       
Pavarin, 2017(56)       
    Pavarin, 2008(57)       
    Pavarin, 2013(58)       
Ryb, 2009(59)       
Sanvisens, 2014(60)        
van Haastrecht, 
1996(61)        
Vlahov, 2008(62)     NA  
Wang, 2005(63)       
Higher risk of bias/ 
Lower quality of 
reportingc
9/21 (42.9%) 3/21 (14.9%) 3/21 (14.9%) 11/21 (52.4%) 10/17 (58.8%)
13/21 
(61.9%) 16/21 (76.2%)
Note. Full details of the risk of bias and quality of study reporting assessment are available in Appendix H, noting that studies with insufficient information to evaluate each criteria were 
deemed ‘higher risk of bias’/’lower quality of reporting’;  denotes lower risk of bias or lower quality of reporting;  denotes higher risk of bias or higher quality of reportinga ‘Entire cohort’ 
refers to reporting for sample of interest in the original study which may include people who do not consume cocaine; ‘cocaine sub-cohort’ refers to reporting where mortality outcomes were 
reported for the subsample of interest for this paper (i.e., people with regular/problematic cocaine use) but whom may not be the primary focus of the paper. b Includes 17 cohorts with cause-
specific mortality data; ‘NA’ denotes cohorts where cause-specific mortality data were not collected; c Totals only include the primary publication if there are multiple publications reporting 
on the same cohort. 
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Table 3: Pooled all-cause and cause-specific CMRs and SMRs for people with regular/problematic cocaine use, stratified by sex, age, drug use characteristics and region






















Overall 16 69,954a 1.24 (0.86-1.78) 98.8%
(22, 39-41, 43, 46, 
48, 51, 52, 54-56, 
60-63)
16 (6) 69,932a 6.13 (4.15-9.05) 99.0% (39-43, 46, 48, 51, 52, 54-56, 60-63)
Sex
Women 6 25,217b 0.66 (0.54-0.81) 55.6% (22, 40, 43, 52, 54, 58) 6 (3) 25,202
b,c 4.59 (2.68-7.87) 94.2% (40, 42, 43, 52, 54, 57)
Men 6 37,041b 0.89 (0.50-1.56) 98.3% (22, 40, 43, 52, 54, 58) 6 (4) 37,056
b 3.42 (2.86-4.10) 77.5% (40, 42, 43, 52, 54, 57)
Age
    < 30 2 3,677 0.67 (0.16-2.89) 97.1% (21, 46) 2 (1) 3,677 7.75 (5.67-10.58) 0.0% (21, 46)
    ≥ 30 3 8,358 1.01 (0.49-2.09) 81.5% (21, 46, 57) 3 (1) 8,358 3.09 (1.77-5.37) 69.4% (21, 46, 57)
Lifetime cocaine injection 5 2,679a 3.60 (3.32-3.90) 88.4% (48, 55, 61-63) 5 (0) 2,679a 13.74 (12.67-14.90) 91.2% (48, 55, 61-63)
Cocaine dependence/use disorder 8 64,286 1.09 (1.07-1.13) 98.4% (22, 39, 40, 43, 46, 54, 56, 60) 8 (5) 64,286 3.24 (3.15-3.33) 97.6%
(22, 39, 40, 43, 46, 
54, 56, 60)
GBD region*
High-Income North America 7 52,006 1.56 (0.83-2.95) 99.2% (22, 39, 48, 52, 55, 62, 63) 7 (1) 51,984 5.13 (2.34-11.25) 99.5%
(39, 42, 48, 52, 55, 
62, 63)
Western Europe 8 17,817a 0.93 (0.49-1.78) 98.6% (40, 41, 43, 51, 54, 56, 60, 61) 8 (4) 17,817
a 6.01 (4.16-8.68) 94.6% (40, 41, 43, 51, 54, 56, 60, 61)
Tropical Latin America 1 131 2.28 (1.57-3.33) - (46) 1 (1) 131 14.75 (9.92-21.17) - (46)
Cause-specific mortality
Drug-relatedc 8 16,857 0.34 (0.10-1.15) 98.6% (41, 44, 46, 47, 49, 55, 56, 63) 8 (2)
c c c c
Suicide 8 100,854 0.07 (0.04-0.10) 72.6% (21, 23, 41, 49, 52, 56, 59, 63) 8 (2) 100,854 6.26 (2.84-13.80) 94.4%
(21, 22, 46, 52, 56, 
59)
Accidental injury 6 64,177 0.09 (0.04-0.22) 95.4% (21, 22, 46, 52, 56, 59) 6 (3) 64,177 6.36 (4.18-9.68) 71.9%
(21, 42, 46, 52, 56, 
59)
Cardiovascular disease 4 14,085 0.13 (0.07-0.24) 77.3% (21, 49, 60, 63) 4 (1) 14,085 1.83 (0.39-8.57) 96.7% (21, 49, 60, 63)
Homicide 3 14,487 0.09 (0.01-0.54) 98.4% (21, 46, 59) 3 (1) 14,487 9.38 (3.45-25.48) 90.1% (21, 46, 59)
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AIDS-related 7 7,293 0.28 (0.12-0.63) 95.1% (41, 45, 46, 49, 56, 60, 63) 6 (1) 6,576 23.12 (11.30-47.31)
g 90.1% (41, 45, 46, 56, 60, 63)
Cancer 5 14,763 0.11 (0.05-0.25) 87.1% (21, 49, 56, 60, 63) 5 (2) 14,763 1.49 (0.70-3.16) 85.5% (21, 49, 56, 60, 63)
Respiratory disease 5 6,217 0.09 (0.04-0.17) 63.2% (41, 45, 49, 56, 63) 1 (1)f 852 24.12 (6.03-96.43) - (56)
Digestive diseases 3 13,140 0.14 (0.03-0.73) 96.1% (21, 49, 63) 1 (1)f 11,905 1.90 (1.20-2.89) - (21)
Liver-relatedd 3 4,666 0.06 (0.01-0.55) 99.9% (45, 46, 60) 3 (0) 4,666 3.36 (0.51-22.10) 92.5% (45, 46, 60)
Note. 
* Regions are defined as per the Global Burden of Disease (GBD) project. No studies were found for the following GBD regions: Central Asia, Central Europe, Eastern Europe, Australasia, High-
Income Asia Pacific, Southern Latin America, Andean Latin America, Caribbean, Central Latin America, North Africa & Middle East, South Asia, East Asia, Oceania, Southeast Asia, Central Sub-
Saharan Africa, Eastern Sub-Saharan Africa, Southern Sub-Saharan Africa or Western Sub-Saharan Africa. 
a Except for van Haastrecht,1996(61), all studies reported the N of people who reported regular/problematic cocaine use. 
b Except for Arendt, 2011(40), all studies reported the N of people who reported regular/problematic cocaine use. 
c Though study estimates were available for SMR, these were deemed unstable and therefore not included. See Appendix L for the pooled estimate using author reported SMRs. It should be 
noted that drug poisoning deaths, for some studies, could include poisoning due to any drug and mental and behavioural disorders due to psychoactive substance use and other causes deemed 
by the authors to be drug-related (see Appendix J for ICD codes where reported).  
d There is partial overlap with digestive diseases deaths, but liver-related deaths includes those that were specified identified as liver related whereas digestive diseases deaths included any 
deaths within a broader definition encompassing the digestive system (i.e., Chapter 10 of ICD-10 codes). 
e The number in brackets denotes the number of cohorts where SMRs were reported by the authors, noting we imputed SMRs for those cohorts where these data were not reported (see 
Appendix L for pooled estimates using only author-reported SMRs. 
f Due to the nature of GBD classifications, expected number of deaths was unable to be estimated resulting in no imputed SMRs to be calculated.
g Tyndall, 2001(49) excluded as estimate was not logical. 
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Table 4: Meta-regression of potential sources of heterogeneity in the pooled all-cause crude mortality rate (CMR) and standardised mortality ratio (SMR)
Crude mortality rate Standardised mortality ratio
N studies Coefficient (SE) Adj. R2 P N studies Coefficient (SE) Adj. R2 P
Sample characteristics at baseline
% Women 9 0.194 (0.543) - 9.76% 0.576 9 0.038 (0.051) 39.96% 0.045
% Injecting 8 5.871 (3.272) 68.62% 0.019 8 3.091 (2.472) 17.35% 0.208
Type of cocaine use - 1.54% 3.19%
Cocaine/Cocaine and crack cocaine 16 ref 16 ref
Speedball/Cocaine and Heroin 6 1.383 (0.546) 0.422 2 2.113 (1.400) 0.276
Geographic region   1.20% - 7.77%
% Western Europe 8 ref 8 ref
% High-Income North America 7 1.689 (0.755) 0.262 7 - 0.207 (0.494) 0.682
% Tropical Latin America 1 2.447 (2.199) 0.337 1   0.844 (0.995) 0.412
Study characteristics
Year of final follow-up 16 0.939 (0.034)  12.54% 0.103 16 0.925 (0.035) 16.88% 0.056
Sample size 15 1.000 (< 0.001)  - 7.82% 0.797 15 1.000 (< 0.001)   0.29% 0.345
Person years 16 1.014 (0.038)  - 6.45% 0.713 16 0.973 (0.038) - 4.64% 0.502
Recruitment setting -14.62% 20.51%
Treatment clinics and other health 
services
6 ref 6 ref
Hospital 3 0.750 (0.492) 0.664 3 0.247 (0.146) 0.034
Other 7 0.961 (0.489) 0.939 7 0.587 (0.268) 0.264
Sampling frame 34.92% 24.65%
       National/sub-national 9 ref 9 ref
       City 7 2.776 (0.985) 0.012 7 2.579 (1.042) 0.034
Note. Regions are defined as per the Global Burden of Disease (GBD) project. No studies were found for the following GBD regions: Central Asia, Central Europe, Eastern 
Europe, Australasia, High-Income Asia Pacific, Southern Latin America, Andean Latin America, Caribbean, Central Latin America, North Africa & Middle East, South Asia, East 
Asia, Oceania, Southeast Asia, Central Sub-Saharan Africa, Eastern Sub-Saharan Africa, Southern Sub-Saharan Africa or Western Sub-Saharan Africa.  Ref: reference category; 
SE: standard error
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Figure 1. PRISMA flow diagram of studies reporting on mortality among people with regular or 
problematic cocaine use
Page 33 of 95 Addiction
For Review Only
Cocaine use and mortality
34
Figure 1. Pooled estimates of all-cause crude mortality rates (CMR) per 100 person-years (left) and standardised mortality ratio (SMR) (right) among people with regular 
or problematic cocaine use, overall and by region 
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Figure 3: Pooled estimates of cause-specific crude mortality rates (CMR) per 100 person-years (left) and standardised mortality ratio (SMR) (right) among people with 
regular or problematic cocaine use
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Figure 4: Pooled estimates of cause-specific standardised mortality ratio (SMR) (right) among people with regular or problematic cocaine use
* Imputed SMR was calculated for the study
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Appendix A: PRISMA checklist 
Section/topic # Checklist item Reported on page # 
TITLE 
Title 1 Identify the report as a systematic review, meta-analysis, or both. 1
ABSTRACT 
Structured summary 2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, 
and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number. 
3-4
INTRODUCTION 
Rationale 3 Describe the rationale for the review in the context of what is already known. 5
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS). 
6
METHODS 
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number. 
7; Appendix 
B p.6-7
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 




Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) 
in the search and date last searched.
7; Appendix 
C p. 9
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. Appendix D 
p. 9
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis). 
7-8
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators. 
8
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made. 
9-10
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis. 
9; Appendix 
G pp. 15-16
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). 9-10
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Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis. 
10
Section/topic # Checklist item Reported on page # 








Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram. 
Figure 1




Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). 12-16; Table 
2
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot. 
Figure 2-3; 
Appendix J 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. 16-23; Table 
3; Figure 2-3
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). Table 2
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). Table 4
DISCUSSION 
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers). 
24-25
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias). 
25-26
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. 27
FUNDING 
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic 
review. 
28
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Appendix B: Description of methods in PROSPERO (ID: CRD42018094623)
The aim of this project will be an update of global reviews of available data on all-cause and cause-
specific mortality among people who use cocaine. The previous reviews include studies published 
from 1980 until 2008 new searches will be undertaken to include studies published from 2009 to 
current.  
The Medline, Embase and PsycINFO peer-reviewed literature databases will be searched using the 
OVID™ interface/platform for relevant articles published from the time-periods 2009 till current. 
Articles of interest comprise those likely to contain data describing all-cause and cause-specific crude 
mortality rates (CMR) and/or standardised mortality ratios (SMR) among people who use cocaine. 
Sets of search strings incorporating both keywords and Medical Subject Headings (MeSH terms) 
reflecting drug type and mortality epidemiology from the previous reviews will be revised and 
expanded for this updated search. Searches will be limited to human literature. No other restrictions 
will be applied to the search; citations for papers in languages other than English will be included 
and read via Google Translate. Citations from these searches will be imported into an Endnote™ 
library, and duplicate citations removed. 
To check for missing peer-review literature, reference lists for relevant systematic reviews identified 
in the peer-review literature search will be hand searched for additional papers not already 
identified. A final list of included studies will be distributed to experts to check if any relevant studies 
are missed. 
Each set of search results (title and abstract) will first be screened by one team member in 
Covidence. All papers marked as excluded will be reviewed by a second person to ensure accuracy in 
first-pass screening. Each study for full-text screening will be reviewed in full by two people. 
Conflicts will be resolved through discussion and referral to a third party if needed.
Data will be independently extracted into an Excel worksheet template by one member of the 
research team and checked by a second member of the team. Bibliographic information will be 
extracted in addition to study specific information. Data entry will be standardized by use of a 
manual, which contains data entry rules. Where data are incomplete, authors will be contacted via 
email to obtain additional information. 
Variables extracted will include study information and sample information (treatment status, HIV 
status, sex, percentage of sample injecting, treatment engagement). Crude mortality rates (CMRs) 
and standardized mortality ratios (SMRs) will be extracted as mortality measures. Cause of death 
information will be extracted for AIDS, overdose, suicide, traumatic (accident, homicide, injury, 
violence and poisoning), disease-related deaths, and other key categories. Disease-related deaths 
will be recoded according to the following categories; cardiovascular (endocarditis, myocardial 
infarction, circulatory system disease and cardiovascular disease), cerebrovascular, respiratory 
(pneumonia and chronic respiratory disease), liver (cirrhosis, viral hepatitis and liver disease), cancer 
(neoplasm, tumour and carcinoma), digestive (digestive system disease, nephritis and haemorrhage 
from duodenal ulcer), nervous system disease and other diseases (tuberculosis, bacterial infection, 
unspecified ‘other disease’ or ‘natural causes’ and when disease categories are not separated).
The quality index used in the previous reviews will be adopted for consistency. The quality index 
assesses each study on nine individual criteria: case ascertainment, measurement, diagnosis, 
estimate, numerator and denominator, data catchment, completeness, representativeness and 
age/sex variables. Each criterion will include a rating scale and the individual scores tallied to provide 
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an overall quality score. Study information necessary for quality assessment will be extracted to the 
Excel template. The greater the quality score, the higher the methodological quality of the study.  
Mortality estimates from higher rating studies may be given additional weighting in the calculation 
of final estimates. Quality estimates may also be used to undertake sensitivity analyses. 
Crude mortality rates will be calculated as per 100 person-years. Where person-years are not 
reported nor made available by the authors, an approximate person-year of follow-up will be 
calculated, with the assumption that deaths occurred halfway through the follow-up period, so that 
each case contributes half the person-year follow-up of survivors. 
Estimates will be analysed in subgroups according to population type (for example, estimates from 
cohorts recruited on the basis of having a chronic physical health condition associated with a high 
mortality rate may be considered separately). Random-effects meta-analyses to determine pooled 
all-cause and cause-specific CMR and SMR estimates will be performed using STATA. This approach 
uses inverse variance weighting to calculate: fixed- and random effects pooled summary estimates; 
confidence limits; a test for differences between study effects; and an estimate of between-study 
variance. The random effects model allows for heterogeneity between as well as within studies; 
expecting high levels of heterogeneity between cohorts, the random-effects model will be used in all 
meta-analyses, with confirmation through the heterogeneity c2 and I-squared statistic. To 
investigate the source of this heterogeneity in an attempt to reduce it, cohorts may be divided into 
subsamples (e.g., by sex, age group, treatment status and HIV status) and/or these factors studied as 
possible risk factors for mortality via meta-regression in Stata.
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Appendix C: Description of databases used
Database Information
Medline Compiled by the U.S. National Library of Medicine (NLM) and published on the Web 
by Community of Science, MEDLINE® is the world's most comprehensive source of 
life sciences and biomedical bibliographic information. It contains nearly eleven 
million records from over 7,300 different publications from 1965 to November 16, 
2005.
(Source: http://medline.cos.com/docs/abmedl.shtml)
EMBASE EMBASE is a biomedical and pharmacological database. 
The EMBASE journal collection is international with over 5,000 biomedical journals 
from 70 countries. EMBASE contains over 11 million records from 1974 to present. 
EMBASE features comprehensive coverage of:
• Drug Research, Pharmacology, Pharmacy, Pharmacoeconomics, Pharmaceutics and 
Toxicology
• Human Medicine (Clinical and Experimental)
• Basic Biological Research
• Health Policy and Management
• Public, Occupational and Environmental Health
• Substance Dependence and Abuse
• Psychiatry
• Forensic Science




PsychINFO PsycINFO is an abstract database of psychological literature from the 1800s to the 
present.  More than 2.4 million records as of January 2008, including journals, books 
and dissertations.  Over 2150 journal titles covered, 98% peer-reviewed; aso books 
and dissertations.  
(Source: http://www.apa.org/psycinfo/)
Page 44 of 95Addiction
For Review Only
9
Appendix D: Search strings and number of results for electronic literature 
searches 
Database Search group Search terms
CocaineCocaine
exp Cocaine/ or exp Crack Cocaine/ or exp Cocaine-Related 
Disorders/ or exp Cocaine Smoking/
Mortal$ or fatal$ or death$ 
Medline*
Mortality
exp DEATH/ or exp "CAUSE OF DEATH"/ or exp DEATH, SUDDEN/ or 
exp Fatal Outcome/ or exp Mortality/
CocaineCocaine
exp Cocaine/ or exp Cocaine Dependence/ or exp Cocaine 
Derivative/ 
Mortal* or fatal* or death* 
EMBASE#
Mortality
exp DEATH/ or exp "CAUSE OF DEATH"/ or exp ACCIDENTAL DEATH/ 
or exp SUDDEN DEATH/ or exp Fatality/ or exp Mortality/
CocaineCocaine
exp Cocaine/ or exp Crack Cocaine/
Mortal* or fatal* or death* 
PsychINFO^
Mortality
exp "DEATH AND DYING"/ or exp Mortality/ or exp Mortality Rate
*  ‘key-words’ in lowercase, ‘MeSH’ terms in bold # ‘key-words’ in lowercase, ‘EMTREE’ terms in bold
^ ‘key words’ in lowercase, explode terms in bold
Search terms Database
EMBASE Medline PsycINFO
1. Cocaine +mortality 1980 600 228
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Appendix E: Inclusion and exclusion criteria for studies
Inclusion criteria for the study population comprised:
 Cohort studies of people using cocaine (where ≥90% of the sample report use of the substance 
of interest; people may report using multiple drugs);
 Cohort studies that are based on a sub-group of people who use cocaine (e.g. people who use 
cocaine who are incarcerated). 
 Cohort studies that are not based on drug use (e.g. a cohort of homeless people), but a 
cocaine-using sub-group is identified, and results are presented separately for this sub-group. 
 Case-control studies where cases are defined by cocaine use and mortality is reported for 
cases and controls separately 
 Clinical trials of interventions to treat cocaine use disorder (randomised controlled trials; non-
randomised trials) where mortality may be reported at follow-up. Interventions may include 
pharmacotherapies or non-pharmacological treatments
 Secondary publications of an included cohort where the outcomes are not mortality (these 
may be used to assess risk of bias or to extract other baseline/demographic data not reported 
in the primary publication). 
Inclusion criteria for the study outcome comprised of:
 Reporting raw mortality data (all-cause or cause-specific) or studies where such data can be 
obtained via contacting study authors.
Exclusion criteria comprised of:
 Cohort studies with a sample of less than 30 participants.
 Case reports/case series of drug-related deaths.
 Works that do not present original data (e.g. letters to the editor, editorials, commentaries)
 Works that do not present mortality data and where data could not be obtained via contacting 
study authors. 
 Systematic reviews (although identified relevant reviews were handsearched for relevant 
studies which will be assessed independently against the inclusion/exclusion criteria)
 Studies where use of cocaine and mortality are not reported for the same sample of people
 Studies where it is unclear that everyone in the cohort reported intentional use of cocaine.
 Clinical trials of interventions for non-substance use disorders that are within a cocaine cohort 
e.g. clinical trials of HCV medicines in a cocaine cohort.
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 Studies where the cohort was defined on the basis of acute care for overdose/poisoning.
 Studies where the cohort was defined by a population that has increased risk of mortality 
(e.g., severe health presentations or conditions, cardiovascular presentations related to 
cocaine exposure and being HIV positive) 
 Studies where cohort reports cocaine use but it is not defined as regular or problematic.
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Appendix F: Cohort studies not included in main analyses
Table F1. List of identified cohort subpopulations not included in the main analyses (n=7)
Study Country Years 
conducted










United States 2002-2005 People who presented for cocaine-induced chest pains, 
identified through a positive cocaine urine screen, to the 





United States 2011-2014 People with heart failure presenting to Grady Memorial 
Hospital, Atlanta with a positive cocaine urine toxicology test 
between 2011-2014
268 260.5* 24.25% 54 
(mean)
3. Nguyen, 20173 United States 1993-2012 People hospitalised for acute decompensated heart failure at 
Michael E. DeBakey Veterans Affairs Medical Center, Houston 
between 1993-2012 with ICD coding of cocaine use and 
positive cocaine urine toxicology screen
90 892.539* 1.1% 55.5
4. Peralta, 2014^4 United States NR People with cocaine-induced chest pain randomised to either 
coronary computed tomographic angiography or standard of 
care protocol 
202 601.5*
5. Campa, 20165 United States NR People with HIV from the Miami Adult Studies on HIV (MASH) 
cohort who self-reported cocaine use and/or had a positive 
cocaine urine toxicology screen
156 670.8* 31% 46.4
6. Nacher, 20096 French Guiana 1996-2007 People with HIV admitted to Cayenne, Kourou, and Saint 
Laurent du Maroni Hospitals with crack cocaine dependence 
between 1996-2007 in French Hospital Database for HIV  
76
7. Weber, 20157 Switzerland 2007-2013 People with HIV registered prior to April 2007 treated at 
outpatient clinics at five university hospitals and two large 
district hospitals and who self-reported cocaine use
947# 4531.4* 32.73%
Note. *PYFU were not reported by study but calculated using formula within Appendix E; ^ denotes that the study was a randomised controlled trial (RCT); NR denotes that variable was not 
reported by the study; # denotes that the information was additionally provided by authors
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Figure F1.  Forest plots displaying the pooled all-cause CMR per 100 person-years (left) and all-cause SMR (right) with studies containing cohorts based on cardiovascular 
presentations.
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Figure F2. Forest plot displaying the pooled all-cause CMR per 100 person-years with studies that 
reported HIV positive subgroups. 
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Appendix G: Quality of reporting and risk of bias assessment tool
RISK OF BIAS DOMAINS
Description Options Rating
Representativenessa How representative of the population 
are the cohort?
One sample type, one location Higher risk of bias
One sample type, multiple locations Reviewer judgement required - 
Lower risk of bias OR higher risk of 
bias
Multiple sample types, one location Lower risk of bias
Multiple sample types, multiple locations 
Insufficient information to determine
Lower risk of bias
Higher risk of bias
Outcome 
measurement
How was mortality measured? Death registry or death certificate data  Lower risk of bias
Medical record, personal contacts, or other source Higher risk of bias
Insufficient information to determine Higher risk of bias





Was the cohort adequately described in 
terms of age (mean/median, or 
categorical age data) and sex?
No – study did not report age or sex data for sample Lower quality of reporting
Yes – Age and sex data for the sample was reported Higher quality of reporting
Completeness of 
outcome data
Did the study report both numerator 
and denominator for main outcome 
analysis? 
No – Numerator, denominator, or both missing Lower quality of reporting
Yes – numerator and denominator reported for main outcome analysis Higher quality of reporting
Definitions use for 
cause-specific deaths 
reported
Did the study report the definitions used 
for cause-specific deaths i.e. ICD codes 
N/A – the study did not report cause-specific deaths N/A
No – no definitions provided (e.g. the study states only “we calculated 
overdose mortality rates” without explaining how overdose was defined)
Lower quality of reporting
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Yes – The study provides ICD codes or other information to describe the 
definition of cause-specific deaths 
Higher quality of reporting
Note. a Examples of coding for sample representativeness used for guidance comprised:
1. A cohort recruited from a single hospital = one sample type, one location
2. A cohort recruited through drug treatment and harm reduction services in a single city or neighbourhood = multiple sample types, one location
3. A cohort recruited through respondent-driven/street-based/convenience sampling = multiple sample types, multiple locations
4. A cohort identified from a database that includes data on people presenting to treatment from a large geographical area = one sample type, multiple locations 
5. A cohort identified from a database that includes data on people presenting to treatment from a restricted geographical area = one sample type, one location
6. A cohort identified from different databases (e.g., drug treatment database, criminal justice database) from a large geographic area = multiple sample types, 
multiple locations
Exceptions:
7. A cohort comprising a very high-risk population for mortality (e.g., people who are incarcerated) = always single sample type and high risk, regardless of number of 
locations
8. A cohort with insufficient information about sample types/site locations = higher risk of bias 
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Appendix H: Data derived and calculation methods
Crude Mortality Rate (CMR)
If the study failed to report all relevant information related to CMR, the following equations were used to calculate 
the missing information. Confidence interval and standard error calculations were completed on the log scale to bound 
the results between 0 and +∞ and to account for deaths being a rarer event. 
CMR (per 100 PY) = 100 x 
Observed deaths
PYFU
CMR 95% confidence interval:
ln (CMR lci) = ln(CMR) ― 1.96(
1
observed deaths)
ln (CMR uci) = ln(CMR) + 1.96(
1
observed deaths)
CMR standard error: 
SE (lnCMR) =  
1
observed deaths
Where: PY = person years; PYFU = person years of follow-up; lci = lower confidence interval; uci = upper confidence 
interval; SE = standard error. 
Studies that reported deaths and follow up, but not person years
For studies that did not report person years, PYFU were estimated. 
The hierarchy of information used to calculate PYFU was 1) drug-specific median FU, 2) drug-specific mean FU, 3) 
cohort median FU, 4) cohort mean FU, 5) reported FU period then 6) study length. 
Due to the proportion of mortality within the cohorts, median was preferred over mean to minimise the potential 
that the calculated PYFU would be more reflective of the proportion of the cohort who were alive at the conclusion 
of FU/the study, than the proportion who died. As there were studies who following people who use more than one 
type of drug, drug-specific data was preferred to better reflective our population of interest; people with regular or 
problematic use of cocaine. Reported FU period and study length were lower on the hierarchy as there is more 
potential of bias due to an assumption of when deaths occurred being needed. Reported FU period was given higher 
preference as the data would be more informative than study length.  Where median or mean follow-up period was 
reported, person year follow up was calculated using:  
PYFU = N x (median or mean FU)
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For example, if a study reported that people who used cocaine (N = 100) were followed for a median of 2.5 years, 
PYFU would be calculated as:
PYFU = 100 x 2.5 years = 250 PYFU
For studies where there was no median or mean follow-up period, the study reported follow-up period or study 
length was used to calculate PYFU using (assuming all deaths occurred halfway through follow-up):  
PYFU = (n𝑎𝑙𝑖𝑣𝑒 x study period) + (n𝑑𝑒𝑎𝑑 x 
study period
2 ) 
For example, if a study of 200 people who used cocaine reported that there were 23 deaths within the 6 years of 
follow-up, PYFU would be calculated as:
PYFU = ((200-23) x 6) + (23 x (6/2)) = (177 x 6) + (23 x 3) = 1131 PYFU
This was our a priori hierarchy for selection of information. However, when we extracted the data, we found no 
studies that reported median or mean, and thus we were required to use reported FU period and study length.
Standardised Mortality Ratio (SMR)
If the study failed to report all relevant information related to SMR, the following equations were used to calculate 
the missing information. 
SMR =  
Observed deaths
Expected deaths
To calculate missing confidence intervals, OpenEpi SMR calculator was used (www.openepi.com/S MR/SMR.htm). 
OpenEpi is an online, open-source tool created for epidemiologic calculations. The confidence intervals calculated via 
the Mid-P exact test was used to fill in the missing information. More information can be located on their website 
about the test (http://www.openepi.com). 
SMR standard error: 
SMR SE =
(SMR uci ― SMR lci)
3.92  
Imputing SMRs using data from the Global Burden of Disease study 
When CMR was able to be calculated but no relevant SMR data was reported, a SMR was estimated using Global 
Burden of Disease 2017 (GBD) data. To be able to estimate SMR, all deaths were assumed to occur at the midpoint 
of the study period. GBD data was accessed through http://ghdx.healthdata.org/gbd-results-tool and matched as 
closely as possible to the location of study, age range of participants at midpoint and midpoint year of the study. As 
cocaine use was limited to problematic or harmful use, a prevalence rate for cocaine dependence was calculated 
using the GBD data as well as a mortality rate for the associated general population. A SMR and relative risk (RR) 
were then estimated by comparing to study CMR to GBD calculated mortality and prevalence rate.




Prior to calculating the RR, the prevalence of cocaine dependence in the population was calculated using Global 
Burden of Disease 2017 (GBD) data. As with the inputting of SMRs, the data was as closely matched to location of 
study, age range of participants and year at study midpoint. Estimating RRs from SMRs was based on the 
methodology outlined by Jones and Swerdlow 8. 
Prevalence in population =  
Total number of users
Total population
To calculate RR and its confidence interval, the following equation was used: 
Relative Risk =
SMR x (1 ― Prevalence in population)
1 ― (Prevalence in population x SMR)

















714 9 3922 0.23
(0.12, 0.44)


















1719 392 11748.63 3.34
(3.02, 3.68)
8680.95 (1719 * 5.05) 4.52
(4.09, 4.99)
Lopez et al., 
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Appendix J: Included studies
Table J1: List of included cohorts (n=21), derived from 28 publications (21 primary and 7 associated secondary publications)
Trials Papers Study Citation Primary study Comments % women Age at baseline % PWID % regular or 
problematic cocaine 
use
1 1 Accurso, 
201514
Accurso AJ, Rastegar DA, Ghazarian SR, Fingerhood MI. Impact of hepatitis C status on 20-year 
mortality of patients with substance use disorders. Addiction Science & Clinical Practice 2015; 10(20): 
1-8. doi:10.1186/s13722-015-0041-6
1 100% dependent on 
cocaine
2 2 Arendt, 201115 Arendt M, Munk-Jorgensen P, Sher L, Jensen SOW. Mortality among individuals with cannabis, 
cocaine, amphetamine, MDMA, and opioid use disorders: A nationwide follow-up study of Danish 
substance users in treatment. Drug and Alcohol Dependence 2011; 114(2-3): 134-9.
1 100% dependent on 
cocaine
3 3 Barrio, 20139 Barrio G, Molist G, de la Fuente L, et al. Mortality in a cohort of young primary cocaine users: 
Controlling the effect of the riskiest drug-use behaviors. Addictive Behaviors 2013; 38(3): 1601-4. 
doi:10.1016/j.addbeh.2012.10.007
1 100% report primary 
drug used as cocaine
4 4 Bohnert, 
201716
Bohnert KM, Ilgen MA, Louzon S, McCarthy JF, Katz IR. Substance use disorders and the risk of suicide 
mortality among men and women in the US Veterans Health Administration. Addiction 2017; 112(7): 
1193-201. doi:10.1111/add.13774
1 3.87% 100% dependent on 
cocaine
5 5 Callaghan, 
201310
Callaghan RC, Gatley JM, Veldhuizen S, Lev-Ran S, Mann R, Asbridge M. Alcohol- or drug-use disorders 
and motor vehicle accident mortality: a retrospective cohort study. Accident; analysis and prevention 
2013; 53: 149-55. doi:10.1016/j.aap.2013.01.008




Callaghan RC, Cunningham JK, Verdichevski M, Sykes J, Jaffer SR, Kish SJ. All-cause mortality among 
individuals with disorders related to the use of methamphetamine: A comparative cohort study. Drug 
and Alcohol Dependence 2012; 125(3): 290-4. doi:10.1016/j.drugalcdep.2012.03.004
0 Secondary paper of Callaghan, 2013 – 
same recruitment method in similar 
timeframe resulting in potentially both 
including the same participants
100% dependent on 
cocaine
6 7 de la Fuente, 
201418
de la Fuente L, Molist G, Espelt A, et al. Mortality risk factors and excess mortality in a cohort of 
cocaine users admitted to drug treatment in Spain. Journal of Substance Abuse Treatment 2014; 
46(2): 219-26. doi:10.1016/j.jsat.2013.07.001
1 17.9% 31.0 (mean) 23.1% 100% dependent on 
cocaine
8 Brugal, 201619 Brugal M, Molist G, Sarasa-Renedo A, et al. Assessing gender disparities in excess mortality of heroin 
or cocaine users compared to the general population. International Journal of Drug Policy 2016; 38: 
36-42. doi:10.1016/j.drugpo.2016.10.009
0 Secondary paper of de la Fuente, 2014 - 
same recruitment method within similar 
timeframe resulting in same participants 
being double counted
100% dependent on 
cocaine
9 Molist, 201820 Molist G, Brugal MT, Barrio G, et al. Effect of ageing and time since first heroin and cocaine use on 
mortality from external and natural causes in a Spanish cohort of drug users. International Journal of 
Drug Policy 2018; 53: 8-16. doi:10.1016/j.drugpo.2017.11.011
0 Secondary paper of de la Fuente, 2014 – 
same recruitment method within similar 
timeframe resulting in same participants 
being double counted
100% dependent on 
cocaine
10 Colell, 201821 Colell E, Domingo-Salvany A, Espelt A, Pares-Badell O, Brugal MT. Differences in mortality in a cohort 
of cocaine use disorder patients with concurrent alcohol or opiates disorder. Addiction 2018; 113(6): 
1045-55. doi:10.1111/add.14165
0 Secondary paper of de la Fuente, 2014 – 
same recruitment method within similar 
timeframe resulting in same participants 
being double counted
100% dependent on 
cocaine
7 11 Dias, 201122 Dias AC, Araujo MR, Dunn J, Sesso RC, de Castro V, Laranjeira R. Mortality rate among crack/cocaine-
dependent patients: A 12-year prospective cohort study conducted in Brazil. Journal of Substance 
Abuse Treatment 2011; 41(3): 273-8. doi:10.1016/j.jsat.2011.03.008
1 11.45% 100% dependent on 
cocaine
8 12 Gossop, 200223 Gossop M, Stewart D, Treacy S, Marsden J. A prospective study of mortality among drug misusers 
during a 4-year period after seeking treatment. Addiction 2002; 97(1): 39-47. doi:10.1046/j.1360-
0443.2002.00079.x
1 100% report regular 
use of cocaine
9 13 Hayashi, 
201611
Hayashi K, Dong H, Marshall BD, et al. Sex-Based Differences in Rates, Causes, and Predictors of Death 
Among Injection Drug Users in Vancouver, Canada. American Journal of Epidemiology 2016; 183(6): 
544-52. doi:10.1093/aje/kwv207
1 100% 100% report 
injecting cocaine in 
past 6 months
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14 Tyndall, 200124 Tyndall MW, Craib KJP, Currie S, Li K, O'Shaughnessy MV, Schechter MT. Impact of HIV infection of 
mortality in a cohort of injection drug users. Journal of Acquired Immune Deficiency Syndrome 2001; 
28(4): 351-7. doi:10.1097/00126334-200112010-00008
0 Secondary paper of Hayashi, 2016 – 
both papers utilised same database of 
individuals (VIDUS) with overlapping 
recruitment periods resulting in 
duplicate data within the 2 papers 
100% report 
injecting cocaine in 
past 6 months
10 15 Hser, 201225 Hser YI, Kagihara J, Huang D, Evans E, Messina N. Mortality among substance-using mothers in 
California: a 10-year prospective study. Addiction 2012; 107(1): 215-22. doi:10.1111/j.1360-
0443.2011.03613.x
1 100% 100% dependent on 
cocaine
11 16 Lopez, 200412 Lopez D, Martineau H, Palle C. Mortality of individuals arrested for heroin, cocaine or crack use, 2004. 1 100% arrested for 
using cocaine
12 17 Markota, 
201626
Markota M, Croarkin PE, Bobo WV. Increased 5-year all-cause mortality in youth with positive urine 
cocaine drug screens. Journal of the American Academy of Child and Adolescent Psychiatry 2016; 55 
(10 Supplement 1): S148. doi:10.1016/j.jaac.2016.09.151
1 40% 100% tested positive 
for cocaine use
13 18 Martell, 200927 Martell BA, Orson FM, Poling J, et al. Cocaine vaccine for the treatment of cocaine dependence in 
methadone-maintained patients: A randomized, double-blind, placebo-controlled efficacy trial. 
Archives of General Psychiatry 2009; 66(10): 1116-23. doi:10.1001/archgenpsychiatry.2009.128
1 33.3% 100% dependent on 
cocaine
14 19 Nielsen, 
201128
Nielsen SF, Hjorthoj CR, Erlangsen A, Nordentoft M. Psychiatric disorders and mortality among people 
in homeless shelters in Denmark: A nationwide register-based cohort study. The Lancet 2011; 
377(9784): 2205-14. doi:10.1016/S0140-6736(11)60747-2
1 20.95% 100% dependent on 
cocaine
15 20 O’Driscoll, 
200129
O'Driscoll PT, McGough J, Hagan H, Thiede H, Critchlow C, Alexander ER. Predictors of accidental fatal 
drug overdose among a cohort of injection drug users. American Journal of Public Health 2001; 91(6): 
984-7.
1 71.48% 100% reported 
primary drug 
injected consisted of 
cocaine
16 21 Pavarin, 
201730
Pavarin RM, Fioritti A. Mortality Trends among Cocaine Users Treated between 1989 and 2013 in 
Northern Italy: Results of a Longitudinal Study. Journal of Psychoactive Drugs 2017; 50(1): 72-80. 
doi:10.1080/02791072.2017.1365976




Pavarin RM. Cocaine consumption and death risk: A follow-up study on 347 cocaine addicts in the 
metropolitan area of Bologna. Annali-Istituto Superiore di Sanita 2008; 44(1): 91-8.
0 Secondary paper of Pavarin, 2017 – 
same recruitment method in similar 
timeframes leading to potential overlap 
of participants between papers 




Pavarin RM. Mortality risk for cocaine abusers in relation to heroin use: A follow-up study. Substance 
Use & Misuse 2013; 48(9): 702-10. doi:10.3109/10826084.2013.786731
0 Secondary paper of Pavarin, 2017 – 
same recruitment method in similar 
timeframes leading to potential overlap 
of participants between papers
100% dependent on 
cocaine
17 24 Ryb, 200933 Ryb GE, Cooper CC, Dischinger PC, Kufera JA, Auman KM, Soderstrom CA. Suicides, homicides, and 
unintentional injury deaths after trauma center discharge: Cocaine use as a risk factor. Journal of 
Trauma - Injury, Infection and Critical Care 2009; 67(3): 490-6. doi:10.1097/TA.0b013e3181b84430
1 16% 100% tested positive 
for cocaine use
18 25 Sanvisens, 
201413
Sanvisens A, Vallecillo G, Bolao F, et al. Temporal trends in the survival of drug and alcohol abusers 
according to the primary drug of admission to treatment in Spain. Drug and Alcohol Dependence 
2014; 136(1): 115-20. doi:10.1016/j.drugalcdep.2013.12.022
1 26.6% 32 65.8% 100% dependent on 
cocaine
19 26 van 
Haastrecht, 
199634
van Haastrecht HJA, van Ameijden EJC, van den Hoek JAR, Mientjes GHC, Bax JS, Coutinho RA. 
Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and 
HIV-negative drug users. American Journal of Epidemiology 1996; 143(4): 380-91. 
doi:10.1093/oxfordjournals.aje.a008752
1 39.56% 77% 100% reported 
primary drug 
injected consisted of 
cocaine
20 27 Vlahov, 200835 Vlahov D, Wang C, Ompad D, et al. Mortality risk among recent-onset injection drug users in five U.S. 
cities. Substance Use & Misuse 2008; 43(3-4): 413-28. doi:10.1080/10826080701203013
1 100% 100% reported 
primary drug 
injected consisted of 
cocaine
21 28 Wang, 200536 Wang C, Vlahov D, Galai N, et al. The effect of HIV infection on overdose mortality. AIDS 2005; 19(9): 
935-42. doi:10.1097/01.aids.0000171407.30866.22
1 48.84% 100% 100% reported 
primary drug 
injected consisted of 
cocaine
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* PYFU was calculated using formula in Appendix H; a Information from secondary paper was used; b SMR was inputted using GBD 2017 estimates (see Appendix H for more information); c Insufficient data was reported to estimate confidence intervals. 
d‘Drug-related’: note that estimates could include poisoning deaths, deaths attributed to mental and behavioural disorders due to psychoactive substance use, and deaths from other causes that were thought to be drug-related.
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Table J3. ICD codes used to identify each cause-specific death
Study 
(Author,ref)
Drug-related Suicide Accidental Injury Cardiovascular 
disease
Homicide AIDS-related Cancer Respiratory 
disease
Barrio, 20139 - - - - - - - -
Bohnert, 201716 - ICD 10: X60-84, Y87.0 - - - - - -
Brugal, 201619a ICD 9: 291, 292, 303-305, 
E850-869, E929.2, E980, 
427.5b,
514b, 518.4b, 780-799b, 
980b; ICD 10:  F10-F19, F55, 
X40-X49, Y10-Y19, I46b, 
J81b,
J96b, R00-R74b, R76-R99b
- - - - - - -
Callaghan, 201310 - - ICD-9 810–825 (with a 
4th digit of “0” or “2”); 
ICD-10 V20-29 (3rd digit 
of “0” or “4”), V30-79 
(3rd digit of “0” or “5”), 
and V83-86 (3rd digit of 
“0” or “5”)
- - - - -
Colell, 201821a - - - ICD 10: J81, J96, J960, 
J969, J13, J18, J189, 
496, J09, J209, J439, 
J441, J449, J841, J850, 
J90, J988
- ICD 9: 279.5; ICD10: B20, 
B200, B202, B203, B205, 
B206, B207, B208, B209, 
B21, B212, B213, B218, 
B220, B222, B227, B238, 
B24
- -
Dias, 201122 - - - - - - - -
Gossop, 200223 - - - - - - - -
Markota, 201626 - - - - - - - -
Molist, 201820a ICD 9: 291, 292, 303-305, 
427.5b, 514b, 518.4b, 780-
799b, 980.0b, E850-869, 
E929.2, E980; ICD 10: F10-
F19, F55, I46b, J81b, J96b, 
R00-R74b, R76-R99b, X40-
X49, Y10-Y19, Y90-Y91
ICD 9: E950-E959; ICD 
10: X60-X84, Y87.0
ICD 9: E800-E949, E980-
E989; ICD 10: V01-X59, 
Y10-Y34, Y40-Y86, 
Y87.2, Y88, Y89.9
ICD 9: 390-459; ICD 
10: I00-I99
ICD 9: E960-E979, 
E990-E999; ICD 10:  
X85-Y09, Y35-Y36, 
Y87.1, Y89.0-Y89.1 
ICD 9: 140-239; ICD 
10: C00-D49
O’Driscoll, 200129 - - - - - - - -
Pavarin, 201730 - - - - - - - -
Ryb, 200933 - - - - - - - -
Sanvisens, 201413 - - - - - ICD-9: 279.5, 795.8; ICD-
10: B20–B24, R75
ICD-9: 140–154, 156–




Tyndall, 200124c - - - - - - - -
Wang, 200536 - - - - - - - -
a Studies were associated secondary papers of cohort presented in de la Fuente, 201418; b  Codes included as overdose deaths because in Madrid information from the forensic and toxicological register could not be consulted to correct 
the underlying cause of death, and Barcelona consultation had shown that such codes contained mostly overdose deaths. c Study was associated secondary paper of cohort presented in Hayashi, 201611; -: no ICD codes reported.
Page 72 of 95Addiction
For Review Only
37
Appendix K: Relative risk results
Figure K1. Pooled estimates, derived from random effects meta-analysis, of all-cause mortality 
relative risk among people with regular or problematic use of cocaine, overall and by region. 
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Figure K2. Forest plots of cause-specific mortality relative risk among people with regular or 
problematic use of cocaine. 
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Table K1. Summary of pooled estimated relative risks of mortality among people with regular or 
problematic use of cocaine
Pooled mortality 
relative risk (95%CI) I
2 References
All-cause mortality 5.41 (3.65-8.01) 98.9% 9,11-15,17,18,22,26,28-30,35,36
Women 5.24 (3.25-8.44) 95.2% 15,17,18,25,28,31
Men 3.44 (2.86-4.15) 74.3% 15,17,18,26,28,31
GBD Region
High-income North 
America 5.35 (2.80-10.25) 98.4%
11,14,17,26,29,35,36
Western Europe 4.64 (3.24-6.63) 95.4% 9,12,13,15,18,28,30
Tropical Latin America 15.55 (10.26-22.89) - 22
Cause-specific mortality
Drug-relateda 114.60 (55.54-236.47) 91.2% 9,20,22,24,29,30,36
Accidental injury 6.13 (4.02-9.34) 73.5% 10,20,22,26,30,33
Suicide 6.32 (2.79-14.34) 94.1% 9,16,20,24,26,30,33,36
Cardiovascular disease 1.85 (0.39-8.85) 96.7% 13,20,24,36
Homicide 9.80 (3.52-27.25) 89.5% 20,22,33
AIDS-related 13.54 (3.78-48.56) 88.2% 13,21,22,30
Cancer 1.49 (0.70-3.18) 85.2% 13,20,24,30,36
Liver-related 3.39 (0.50-23.02) 92.5% 13,21,22
Cerebrovascular disease - - -
Digestive disease - - -
Nervous system - - -
Respiratory disease - - -
Note. a ‘Drug-related’: note that estimates could include poisoning deaths, deaths attributed to 
mental and behavioural disorders due to psychoactive substance use, and deaths from other causes 
that were thought to be drug-related.
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Appendix L: Supplementary results
Table L1. Summary of pooled results using only study-reported CMRs (i.e. not including imputed 









All-cause mortality 10 67,159 1.25 (0.81-1.94) 99.1% 9-13,15,18,22,30,34-36
Womena 4 24,596b 0.67 (0.56-0.81) 44.6% 10,15,18,32
Men 4 36,588b 0.70 (0.33-1.45) 99.0% 10,15,18,32
GBD Region
High-income North America 4 51,288 1.98 (0.83-4.71) 99.6% 10,11,35,36
Western Europe 7 17,292c 0.88 (0.42, 1.85) 98.7% 9,12,13,15,18,30,34t
Tropical Latin America 1 131 2.29 (1.57-3.33) - 22
Cause-specific mortality
Drug-relatedd 3 12,750 0.10 (0.05-0.19) 52.5% 9,19,22
Accidental injury 3 60,985 0.05 (0.02-0.11) 92.1% 10,20,22
Suicide 2 12,619 0.05 (0.04-0.07) 0.0% 9,20
Cardiovascular disease 2 12,850 0.09 (0.05-0.15) 63.2% 13,20
Homicide 2 12,036 0.10 (0.00-16.41) 99.0% 20,22
AIDS-related 4 5,380 0.14 (0.02-0.88) 95.7% 9,13,21,22
Respiratory disease 2 4,304 0.06 (0.04-0.09) 0.0% 9,21
Cancer 2 12,850 0.06 (0.05-0.08) 0.0% 13,20
Digestive disease 1 11,905 0.03 (0.02-0.05) - 20
a Pavarin, 2013 included, but no women died. b Except for Arendt, 2011, all studies reported the N of cocaine-
using participants  c Except for van Haastrecht, 1996, all studies reported the N of cocaine-using participants.  d 
‘Drug related’: note that estimates could include poisoning deaths, deaths attributed to mental and 
behavioural disorders due to psychoactive substance use, and deaths from other causes that were thought to 
be drug-related.
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Table L2. Summary of pooled results using only study-reported SMRs (i.e. not including imputed 










All-cause mortality 7 63,431 5.58 (3.90-7.99) 96.6% 9,15,17,18,22,30,37
Women 3 24,538a 7.00 (3.12-15.68) 96.7% 15,17,18
Men 4 36,603a 3.41 (2.74-4.23) 84.3% 15,17,18,31
GBD Region
High-income North America 2 49,165 3.94 (2.11-7.35) 89.3% 17,37
Western Europe 4 14,135 4.97 (4.51-5.47)  0.0% 9,15,18,30
Tropical Latin America 1 131 14.75 (10.10-21.55) - 22
Cause-specific mortality
Drug-relatedb 2 12,583 44.37 (37.28-52.81) 0.0% 20,30
Accidental injury 3 61,532 5.01 (3.71-6.77) 29.9% 10,20,30
Suicide 2 12,583 9.25 (6.73-12.73) 0.0% 20,30
Cardiovascular disease 2 12,583 2.62 (1.21-5.68) 66.8% 20,30
Homicide 1 11,905 4.17 (1.69-10.25) - 20
AIDS-related 1 678 4.98 (0.70-35.34) - 30
Respiratory disease 1 678 24.12 (6.03-96.43) - 30
Cancer 2 12,583 1.10 (0.61-1.98) 20,30
Digestive disease 1 11,905 1.90 (1.20-2.89) - 20
a Except for Arendt, 2011, all studies reported the N of cocaine-using participants. b ‘Drug related’: note that 
estimates could include poisoning deaths, deaths attributed to mental and behavioural disorders due to 
psychoactive substance use, and deaths from other causes that were thought to be drug-related.
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Figure L1. Pooled estimates, derived from random effects meta-analysis, for all-cause CMR by gender (men only vs. women only) per 100 person-years with studies that 
reported deaths by either gender (left) or both genders (right).
Note: Pavarin, 201332 reported no deaths among women and therefore not included in pooled estimate.
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Figure L2. Pooled estimates, derived from random effects meta-analysis, for all-cause SMR by gender (men only vs. women only) per 100 person-years with studies that 
reported deaths by either gender (left) or both genders (right).
Note: Pavarin, 200831 reported no deaths among women and therefore not included in pooled estimate.
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Figure L3. Forest plot displaying the pooled within-study relative risk of studies reporting all-cause 
crude mortality rates for men v. women (ref) (top) and older people v. younger people (ref) 
(bottom)
Note: Arendt, 201115 was not included in the gender within-study relative risk analysis as they did not report number of 
deaths within men and women
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Figure L4.  Forest plots derived from random effects meta-analysis for younger people (< 30) vs. older people (≥ 30) for all-cause CMR per 100 person-years (left) and all-
cause SMR (right).
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Figure L5. Forest plots derived from random effects meta-analysis by sampling frame: national vs. subnational (including states/provinces) vs. city for all-cause CMR per 
100 person-years (left) and all-cause SMR (right).
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Figure L6.  Forest plots derived from random effects meta-analysis by cocaine form used: cocaine vs. cocaine and crack cocaine vs. speedball vs. cocaine and heroin for 
all-cause CMR per 100 person-years (left) and all-cause SMR (right).
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Figure L7. Bubble plot displaying results of meta-regression analysis examining the impact of proportion of women 
within cohort on CMR per 100PY.
Figure L8. Bubble plot displaying results of meta-regression analysis examining the impact of proportion of people 
who inject drugs within cohort on CMR per 100PY. 
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Figure L9. Meta-regression analysis examining the impact of cocaine form used (ref. Cocaine/Cocaine and Crack 
Cocaine; Cocaine 1 = Speedball/Cocaine and Heroin) on CMR per 100PY.
Figure L10. Meta-regression analysis output examining the impact of GBD region (ref. High-Income North America; 
GBD 1 = Western Europe, GBD 2 = Tropical Latin America) on CMR per 100PY. 
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Figure L11. Bubble plot displaying results of meta-regression analysis examining the impact of final year of study 
follow-up on CMR per 100PY.
Figure L12. Bubble plot displaying results of meta-regression analysis examining the impact of cohort size on CMR 
per 100PY.
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Figure L13. Bubble plot displaying results of meta-regression analysis examining the impact of person-years of 
follow-up on CMR per 100PY.
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Figure L14. Meta-regression analysis examining the impact of recruitment setting (ref. Treatment clinics and other 
health services; Setting 1 = Hospital; Setting 2 = Convenience sampling) on CMR per 100PY.
Figure L15. Meta-regression analysis output examining the impact of study sampling frame (ref. 
National/Subnational, Area 2 = City) on CMR per 100PY. 
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Figure L16. Bubble plot displaying results of meta-regression analysis examining the impact of proportion of 
women within cohort on SMR.
Figure L17. Bubble plot displaying results of meta-regression analysis examining the impact of proportion of 
people who inject drugs within cohort on SMR.
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Figure L18. Meta-regression analysis examining the impact of cocaine form used (ref. Cocaine/Cocaine and Crack 
Cocaine; Cocaine 1 = Cocaine and Heroin) on SMR.
Figure L19. Meta-regression analysis output examining the impact of GBD region (ref. High-Income North America; 
GBD 1 = Western Europe, GBD 2 = Tropical Latin America) on CMR per 100PY. 
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Figure L20. Bubble plot displaying results of a meta-regression analysis examining impact of final year of study 
follow-up on SMR.
Figure L21. Bubble plot displaying results of a meta-regression analysis examining impact of cohort size of follow-
up on SMR.
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Figure L22. Bubble plot displaying results of a meta-regression analysis examining impact of person-years of 
follow-up on SMR.
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Figure L23. Meta-regression analysis examining the impact of recruitment setting (ref. Treatment clinics and other 
health services; Setting 1 = Hospital; Setting 2 = Convenience sampling) on SMR.
Figure L24. Meta-regression analysis output examining the impact of study sampling frame (ref. 
National/Subnational, Area 2 = City) on SMR. 
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